Lexicon Pharmaceuticals Inc (LXRX)
1.74
+0.04
(+2.35%)
USD |
NASDAQ |
May 03, 16:00
1.76
+0.02
(+1.15%)
After-Hours: 20:00
Lexicon Pharmaceuticals Net Income (Quarterly): -48.40M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -48.40M |
December 31, 2023 | -49.76M |
September 30, 2023 | -50.52M |
June 30, 2023 | -44.90M |
March 31, 2023 | -31.93M |
December 31, 2022 | -30.49M |
September 30, 2022 | -23.39M |
June 30, 2022 | -24.59M |
March 31, 2022 | -23.48M |
December 31, 2021 | -25.61M |
September 30, 2021 | -23.12M |
June 30, 2021 | -18.07M |
March 31, 2021 | -20.96M |
December 31, 2020 | -5.495M |
September 30, 2020 | 82.60M |
June 30, 2020 | -69.07M |
March 31, 2020 | -66.61M |
December 31, 2019 | -51.14M |
September 30, 2019 | 226.09M |
June 30, 2019 | -23.02M |
March 31, 2019 | -21.80M |
December 31, 2018 | -16.78M |
September 30, 2018 | -27.40M |
June 30, 2018 | -34.55M |
March 31, 2018 | -41.82M |
Date | Value |
---|---|
December 31, 2017 | -22.32M |
September 30, 2017 | -30.72M |
June 30, 2017 | -35.06M |
March 31, 2017 | -34.89M |
December 31, 2016 | -22.44M |
September 30, 2016 | -36.02M |
June 30, 2016 | -38.11M |
March 31, 2016 | -34.88M |
December 31, 2015 | 86.75M |
September 30, 2015 | -35.28M |
June 30, 2015 | -28.07M |
March 31, 2015 | -28.08M |
December 31, 2014 | -2.933M |
September 30, 2014 | -40.50M |
June 30, 2014 | -26.03M |
March 31, 2014 | -30.84M |
December 31, 2013 | -17.41M |
September 30, 2013 | -31.66M |
June 30, 2013 | -29.08M |
March 31, 2013 | -25.97M |
December 31, 2012 | -24.87M |
September 30, 2012 | -29.54M |
June 30, 2012 | -25.93M |
March 31, 2012 | -29.87M |
December 31, 2011 | -33.84M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-69.07M
Minimum
Jun 2020
226.09M
Maximum
Sep 2019
-16.09M
Average
-25.10M
Median
Net Income (Quarterly) Benchmarks
Windtree Therapeutics Inc | -5.154M |
AIM ImmunoTech Inc | -12.58M |
Perspective Therapeutics Inc | -24.68M |
Protalix BioTherapeutics Inc | -6.044M |
Armata Pharmaceuticals Inc | -19.85M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 1.13M |
Total Expenses (Quarterly) | 46.46M |
EPS Diluted (Quarterly) | -0.20 |
Enterprise Value | 172.75M |
Gross Profit Margin (Quarterly) | 97.26% |
Profit Margin (Quarterly) | -4.28K% |
Earnings Yield | -47.70% |
Normalized Earnings Yield | -47.70 |